Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
UBS
Covington
Farmers Insurance
Chubb
Boehringer Ingelheim

Generated: September 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,006,224

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,006,224 protect, and when does it expire?

Patent 9,006,224 protects AFINITOR and is included in one NDA.

This patent has forty-six patent family members in twenty-three countries.

Summary for Patent: 9,006,224
Title:Neuroendocrine tumor treatment
Abstract: A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.
Inventor(s): Marks; Peter Wayne (Woodbridge, CT), Lebwohl; David (Madison, NJ)
Assignee: Novartis AG (Basel, CH)
Application Number:12/094,173
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,006,224
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,006,224

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis AFINITOR everolimus TABLET;ORAL 022334-003 Jul 9, 2010 RX Yes No   Try a Free Trial   Try a Free Trial TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC   Try a Free Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-001 Mar 30, 2009 RX Yes Yes   Try a Free Trial   Try a Free Trial TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC   Try a Free Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-004 Mar 30, 2012 RX Yes No   Try a Free Trial   Try a Free Trial TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC   Try a Free Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-002 Mar 30, 2009 RX Yes No   Try a Free Trial   Try a Free Trial TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,006,224

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0523658.3Nov 21, 2005
United Kingdom0601082.1Jan 19, 2006
United Kingdom0602747.8Feb 10, 2006
United Kingdom0607942.0Apr 21, 2006
United Kingdom0609272.0May 10, 2006
United Kingdom0609912.1May 18, 2006
06120660Sep 14, 2006
PCT Information
PCT FiledNovember 20, 2006PCT Application Number:PCT/EP2006/068656
PCT Publication Date:May 24, 2007PCT Publication Number: WO2007/057457

International Family Members for US Patent 9,006,224

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006314444   Try a Free Trial
Australia 2010202866   Try a Free Trial
Brazil PI0618808   Try a Free Trial
Canada 2629245   Try a Free Trial
Canada 2933875   Try a Free Trial
China 101360496   Try a Free Trial
China 103446138   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Citi
Boehringer Ingelheim
McKesson
US Department of Justice
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.